按需抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性的长期缓解
本研究比较了按需抗血管内皮生长因子治疗下达到长期缓解的新生血管性年龄相关性黄斑变性患者的就诊特征与未缓解对照组。长期缓解组1型脉络膜新生血管膜占74%、视网膜血管瘤样增生占18.5%,对照组1型占87.5%、无视网膜血管瘤样增生(P=0.036)。长期缓解组中心凹下脉络膜厚度更薄(147 vs 178 μm,P=0.04),就诊时视网膜内积液更多、视网膜下积液更少(P=0.03)。
要点
- 长期缓解组1型脉络膜新生血管膜占74%、视网膜血管瘤样增生占18.5%,对照组分别为87.5%和0%(P=0.036)。
- 长期缓解组中心凹下脉络膜厚度147 μm,对照组178 μm(P=0.04)。
- 长期缓解组就诊时视网膜内积液59.3%、视网膜下积液11.1%,对照组分别为28.1%和34.4%(P=0.03)。
核心结论
- 就诊时存在视网膜血管瘤样增生、脉络膜厚度较薄、视网膜内积液较多及视网膜下积液较少,与接受按需治疗的新生血管性年龄相关性黄斑变性患者达到长期缓解相关。
研究设计与样本
- 比较长期缓解患者与对照组就诊特征的研究;长期缓解定义为按需抗血管内皮生长因子治疗下无视网膜内/视网膜下积液或出血、且荧光素眼底血管造影无渗漏持续超过6个月。
- 对照组包括28例患者的32只眼,按年龄、性别和种族匹配,均未达到长期缓解。
主要发现
- 长期缓解组74%为1型脉络膜新生血管膜、18.5%为视网膜血管瘤样增生;对照组32只眼中28只眼(87.5%)为1型脉络膜新生血管膜、无视网膜血管瘤样增生;两组病变类型总体差异有统计学意义(P=0.036)。
- 长期缓解组就诊时中心凹下脉络膜厚度为147 μm,对照组为178 μm(P=0.04)。
- 长期缓解组就诊时视网膜内积液占59.3%、视网膜下积液占11.1%;对照组分别为28.1%和34.4%(P=0.03)。
关键数值与推荐
- 长期缓解定义:按需抗血管内皮生长因子治疗下无视网膜内/视网膜下积液或出血,且荧光素眼底血管造影无渗漏持续超过6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the presenting characteristics of patients with neovascular age-related macular degeneration with long-term remission (LTR), which was defined as the absence of intraretinal/subretinal fluid, or hemorrhage, and absence of leakage on fluorescein angiography for longer than 6 months while on as-needed antivascular endothelial growth factor treatment. METHODS: The presenting characteristics of patients with LTR were compared with a control group including 32 eyes of 28 age-, gender-, and ethnicity-matched patients who did not achieve LTR. RESULTS: Seventy-four percent of patients in the LTR group had Type 1 choroidal neovascular membrane and 18.5% had retinal angiomatous proliferation. In the control group, 28 eyes had Type 1 choroidal neovascular membrane (87.5%), and none of the patients had retinal angiomatous proliferation; overall, there was a significant difference in lesion types between the 2 groups (P = 0.036). Eyes with LTR at presentation had significantly thinner subfoveal choroidal thickness (147 vs. 178 μm, P = 0.04). There was more intraretinal fluid and less subretinal fluid at the presentation in the remission group (59.3% intraretinal fluid and 11.1% subretinal fluid) compared with the control group (28.1% intraretinal fluid and 34.4% subretinal fluid, P = 0.03). CONCLUSION: The presence of retinal angiomatous proliferation, thinner choroidal thickness, more intraretinal fluid, and less subretinal fluid at presentation were associated with LTR in patients receiving as-needed treatment for age-related macular degeneration.
引用
- Muftuoglu IK, Alam M, You QS, et al. LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2018. PMID: 28221254. doi:10.1097/IAE.0000000000001572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。